On June 18, 2026 Deck Bio, a biotechnology company advancing multi-pMHC targeted T cell engagers for solid tumors, reported its participation in the 8th T-Cell Engager Therapeutics Summit and the BIO International Convention 2026, both taking place in San Diego, California. The company’s leadership team will participate in scientific presentations, panel discussions, and partnering meetings focused on the development of next-generation T cell engager therapies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"T cell engagers have transformed the treatment of hematologic malignancies, but extending that success to solid tumors will require new approaches to target biology and therapeutic design," said Jack Silberstein, Chief Executive Officer and Founder of Deck Bio. "These meetings provide an opportunity to discuss how multi-pMHC targeting may help address some of the longstanding challenges in the field and to share the progress we’re making with our lead program, DBXO-1."

DBXO-1 is a multi-pMHC targeted T cell engager designed to recognize multiple cancer-associated peptide–major histocompatibility complexes (pMHCs) using a single engineered T cell receptor (TCR)-based binder. By targeting multiple independent pMHCs, DBXO-1 is designed to expand patient eligibility and improve durability of response across major solid tumor indications.

Details of Deck Bio’s participation are as follows:

8th T-Cell Engager Therapeutics Summit

Date: June 23-25, 2026
Location: Westin San Diego Bayview
Workshop Leadership: Synchronizing Global Regulatory Strategies through Modelling & Translational Approaches for Next-Generation TCEs – Tuesday, June 23, 2:00 – 4:00 p.m. PT
Scientific Presentation: Expanding the Reach of T Cell Engagers in Solid Tumors through pMHC Multi-Targeting – Wednesday, June 24, 2:00 – 2:30 p.m. PT
BIO International Convention 2026

Date: June 22-25, 2026
Location: San Diego Convention Center
Start-Up Stadium: Deck Bio Pitch – Tuesday, June 23, 2:00 – 4:00 p.m. PT
Panel Discussion: The Therapeutic Modality Puzzle in Oncology: One Size Fits All or Fit to Purpose? – Wednesday, June 24, 4:15 – 5:15 p.m. PT
Deck Bio’s leadership team will be available for partnering and scientific discussions throughout both conferences.

(Press release, Deck Bio, JUN 18, 2026, View Source [SID1234668801])